Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
Abstract Only 40% of patients with advanced ovarian cancer survive more than 5 years. We have previously shown that pitavastatin induces regression of ovarian cancer xenografts in mice. To evaluate whether the response of ovarian cancer cells to pitavastatin is potentiated by farnesyl diphosphate sy...
Guardado en:
Autores principales: | Marwan Ibrahim Abdullah, Mohammed Najim Abed, Alan Richardson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8ca55e1241a04e7ca10cbcd71758b463 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer
por: Elizabeth de Wolf, et al.
Publicado: (2017) -
Inhibition of the mevalonate pathway enhances cancer cell oncolysis mediated by M1 virus
por: Jiankai Liang, et al.
Publicado: (2018) -
Statins and diabetes: focus on pitavastatin
por: Soreiia A. Urazgildeeva
Publicado: (2020) -
Effect of levels of acetate on the mevalonate pathway of Borrelia burgdorferi.
por: Tricia A Van Laar, et al.
Publicado: (2012) -
Pitavastatin: focus on safety and drug interactions
por: Larisa O. Minushkina, et al.
Publicado: (2021)